FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. (Q41318392)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Frauke Zipp

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Heinz Wiendl

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Tobias Bopp

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Valérie Jolivel

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Felix Luessi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Stefan Kraus

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Bettina Trinschek

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Steffen Lerch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Robert Ploen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Magdalena Paterka

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Torsten Roberg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Laura Poisa-Beiro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Luisa Klotz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Esther Witsch

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

2 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1811-1822

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25732840%20AND%20SRC:MED&resulttype=core&format=json

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibitio

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Role of C-C chemokine receptor type 7 and its ligands during neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Treatment of multiple sclerosis with the pregnancy hormone estriol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

IL-1β and TGF-β act antagonistically in induction and differentially in propagation of human proinflammatory precursor CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515574895